| 1280-18 | An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts. | Open |
| 17-1493 | Expanded Access of Neratinib for Use with Capecitabine in Patients with Metastatic Breast Cancer and CNS Metastasis | Open (affiliates only) |
| 17C0034 | A randomized, double blind phase II trial of Radiation Therapy plus Temozolomide and Pembrolizumab with and without HSPPC-96 in newly diagnosed Glioblastoma (GBM) | Open |
| A011502-CIRB-REX | Rex_Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy For Node Positive HER2 Negative Breast Cancer: The ABC Trial | Open (affiliates only) |
| A031102-CIRB | A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (Tip) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (Ti-Ce) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors | Open |
| AGCT1531 | A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors | Open |
| AMGEN359 | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of
Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of
Recurrence (D-CARE) | Open (affiliates only) |
| AMGEN482 | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With
Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly
Diagnosed Multiple Myeloma | Open (affiliates only) |
| ANBL1531 | A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379) | Open |
| ANHL1522 | A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD) | Open |
| APEC1621SC | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) | Open |
| ARO-021 | ARO-021- Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Inducation Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia | Open |
| ASG-22CE-13-2 | A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4 | Open |
| BMT-CTN-1506 | A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML | Open |
| DF-HCC17101-PACE | DF-HCC 17-101: Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer (Protocol #: 17-101) | Open |
| EAY131-A | MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment | Open |
| ETCTN9767-CIRB | An Open Label, Multicenter, Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor, MLN0128 (TAK-228), in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation. | Open |
| FADOI03-2016 | Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer: a Prospective Randomized Open Blinded End-Point (PROBE) Study - The Caravaggio Study | Open |
| FEDR-MF-001FREEDOM | A Phase 3b, Multicenter, Single-Arm, Open-Label Efficacy and Safety Study of Fedratinib in Subjects with DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated with Ruxolitinib. | Open |
| GU15-262 | Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations | Open |
| INCB01158-206 | “A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma” | Open |
| LCCC1725 | A Phase II Study of Durvalumab (MEDI 4736) with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma | Not Open |
| LCCC1907-ATL-COM | Compassionate Use Re-Infusion of ATLCAR.CD30 | Open |
| LCCC1932-ATL-COM | Compassionate Use Infusion of ATLCAR.CD30.CCR4 | Open |
| LOXO-BTK-18001 | A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin’s Lymphoma (NHL) | Open |
| MIRATI-516-003 | A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma | Open |
| NCI-CT018-10129-CIRB | A Phase 2 Study of PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors | Open |
| NRG-GU006 | A PHASE II, DOUBLE-BLINDED, PLACEBO-CONTROLLED RANDOMIZED TRIAL OF SALVAGE RADIOTHERAPY WITH OR WITHOUT ENHANCED ANTI-ANDROGEN THERAPY WITH APALUTAMIDE IN RECURRENT PROSTATE CANCER | Open |
| ODO-TE-B301 | A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane | Open |
| ONC012 | A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer | Open |
| PANTHER | PANTHER: Prospective study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy Naïve mEn with mCRPC Stratified by Race (PANTHER) | Open |
| RTOG1008 | A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors | Closed |
| S1702-CIRB | S1702, CIRB " A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for patients with previously treated Al Amyloidosis | Open |
| SGN22E-002 | A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer | Open |
| UAZ2016-08-02 | A Phase I safety and dose-finding trial of alternate-weekly, self-administered, intravaginal application of 5-fluorouracil and imiquimod for treatment of high-grade cervical intraepithelial lesions | Open |
| UC13-0540 | Afatinib in advanced refractory urothelial cancer | Open |